135 related articles for article (PubMed ID: 22258585)
1. Russian drug law hinders clinical trials.
Katsnelson A
Nature; 2012 Jan; 481(7381):250. PubMed ID: 22258585
[No Abstract] [Full Text] [Related]
2. Multi-regional clinical trials--what are the challenges?
Wang SJ
Pharm Stat; 2010; 9(3):171-2. PubMed ID: 20821408
[No Abstract] [Full Text] [Related]
3. FDA under pressure to relax drug rules.
Ledford H
Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
[No Abstract] [Full Text] [Related]
4. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
5. Drug companies should release data from all trials of licensed drugs, say MPs.
Hawkes N
BMJ; 2013 Jan; 346():f321. PubMed ID: 23325880
[No Abstract] [Full Text] [Related]
6. China cracks down on fake data in drug trials.
Cyranoski D
Nature; 2017 May; 545(7654):275. PubMed ID: 28516939
[No Abstract] [Full Text] [Related]
7. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
8. Managing conflicts of interest: a survival guide for biotechs.
Werner MJ; Price E
Nat Biotechnol; 2007 Feb; 25(2):161-3. PubMed ID: 17375384
[TBL] [Abstract][Full Text] [Related]
9. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
10. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
Asano K; Tanaka A; Sato T; Uyama Y
Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
[TBL] [Abstract][Full Text] [Related]
11. [Legal liability in clinical trials from the legal-pharmaceutical viewpoint].
Amon F
Z Arztl Fortbild (Jena); 1995 Nov; 89(6):638-41. PubMed ID: 8588437
[TBL] [Abstract][Full Text] [Related]
12. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
13. Indian Supreme Court halts approval of new clinical trials until regulatory framework is set up.
Bagcchi S
BMJ; 2013 Oct; 347():f5996. PubMed ID: 24097130
[No Abstract] [Full Text] [Related]
14. Challenges and opportunities in bringing new medications to market for pediatric patients.
Upadhyaya HP; Gault L; Allen AJ
J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
[No Abstract] [Full Text] [Related]
15. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
16. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
17. Industry looks to buck bias in emerging 'adaptive' designs.
Torres C
Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
[No Abstract] [Full Text] [Related]
18. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
Piana C; Kliphuis E; Della Pasqua O
Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
[TBL] [Abstract][Full Text] [Related]
19. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
20. External influences on protocol design.
Spilker B
Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
[No Abstract] [Full Text] [Related]
[Next] [New Search]
